In this study, we selected phosphatidylethanolamine‐binding protein 1 (PEBP1) mRNA as the target gene and delivered it to VSMCs using biomimetic nanovesicles, aiming to activate the NRF2/GPX4 axis, inhibit ferroptosis, and explore their potential in the prevention and treatment of AAA. The gene discussed is GPX4; the disease is triple-A syndrome.